Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,4-galactosyltransferase 2 (B4GALT2) is an enzyme responsible for transferring galactose in a beta-1,4 linkage to acceptor sugars (such as N-acetylglucosamine, glucose, and xylose) during the biosynthesis of glycoconjugates, especially N-acetyllactosamine in glycoproteins and glycolipids. It is a type II membrane glycoprotein localized primarily to the Golgi apparatus, where its N-terminal domain serves as a membrane anchor. B4GALT2 displays exclusive specificity for its donor substrate, UDP-galactose, and its substrate specificity can be modified by the presence of alpha-lactalbumin, though it is not active in lactating mammary tissue. This enzyme plays a crucial role in the construction of complex N-linked oligosaccharides and the carbohydrate moieties of glycolipids. Mutations in B4GALT2 are associated with Ehlers-Danlos syndrome, spondylodysplastic type 2. There are several transcript variants encoding different isoforms of the protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,4-galactosyltransferase 2 (B4GALT2).